Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib-resistant chronic myeloid leukaemia patient harbouring the BCR-ABL1 T315I gatekeeper mutation.

Coude, Marie-Magdelaine; Luycx, Odile; Cariou, Marie-Estelle; Maarek, Odile; Dombret, Hervé; Cayuela, Jean-Michel; Rea, Delphine

Coude, Marie-Magdelaine; Luycx, Odile; Cariou, Marie-Estelle; Maarek, Odile; Dombret, Hervé; Cayuela, Jean-Michel; Rea, Delphine.

Br J Haematol ; 157(3): 407-10, 2012 May.

Article in En | MEDLINE | ID: mdl-22225474

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy; Aged; Benzamides; Drug Resistance; Female; Harringtonines/administration & dosage; Homoharringtonine; Humans; Imatinib Mesylate; Mutation; Neoplasm, Residual; Piperazines/therapeutic use; Pyrimidines/administration & dosage; Pyrimidines/therapeutic use

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Antineoplastic Combined Chemotherapy Protocols Limits: Aged / Female / Humans Language: En Year: 2012 Type: Article

Fulltext

XML

PubMed Links

Search on Google